کد مقاله | کد نشریه | سال انتشار | مقاله انگلیسی | نسخه تمام متن |
---|---|---|---|---|
8516653 | 1556581 | 2018 | 54 صفحه PDF | دانلود رایگان |
عنوان انگلیسی مقاله ISI
Glucagon-like peptide-1 mediates effects of oral galactose in streptozotocin-induced rat model of sporadic Alzheimer's disease
ترجمه فارسی عنوان
اثر متقابل گالاکتوز خوراکی در موش های صحرایی مبتلا به استرپتوزوتوسین مبتلا به آلزایمر اسپادیا
دانلود مقاله + سفارش ترجمه
دانلود مقاله ISI انگلیسی
رایگان برای ایرانیان
کلمات کلیدی
intracerebroventricularGIPSGLTCTXGLP-1RMWMFDGGLP-1GLUTPS1STZAβ1-42ICVfluorodeoxyglucoseHPCAPPCTRDPP-IVGlucagon like peptide-1 receptor18Fluorodeoxyglucosepresenilin 1 - Presenilin 1Adenosine Triphosphate - آدنوزین تری فسفاتATP - آدنوزین تری فسفات یا ATPPassive avoidance test - آزمون اجتناب ناپذیرstreptozotocin - استرپتوزوتوسینSporadic Alzheimer's disease - بیماری آلزایمر اسپورادیکMorris water maze test - تست ماز آب موریسPositron emission tomography - توموگرافی گسیل پوزیترونMemory - حافظهGlucose transporter - حمل و نقل گلوکزintraperitoneal - داخل صفاقیper oral - در طول دهانCNS - دستگاه عصبی مرکزیdipeptidyl peptidase IV - دیپپتیدیل پپتیداز IVSodium glucose cotransporter - سدیم گلوکزcentral nervous system - سیستم عصبی مرکزیSAD - غمگینCortex - قشرCSF - مایع مغزی نخاعیCerebrospinal fluid - مایع مغزی نخاعیcerebral metabolic rate for glucose - میزان متابولیسم مغزی برای گلوکزHippocampus - هیپوکامپ gastric inhibitory polypeptide - پالپپتید مهارکننده معدهPET - پتamyloid precursor protein - پروتئین پیش ماده آمیلوئیglucagon-like peptide-1 - پپتید 1-گلوکاگون-مانندControl - کنترلglucagon like peptide-1 - گلوکاگون مانند پپتید-1
موضوعات مرتبط
علوم زیستی و بیوفناوری
علم عصب شناسی
علوم اعصاب رفتاری
چکیده انگلیسی
Insulin resistance and metabolic dysfunction in the brain are considered to be the pathophysiological core of sporadic Alzheimer's disease (sAD). In line with that fact, nutrients that could have therapeutic effects at this level have been investigated as possible targets in AD therapy. Galactose, an epimer of glucose, may serve as an alternative source of energy, and given orally may stimulate secretion of the incretin hormone glucagon-like peptide-1 (GLP-1). Our preliminary research indicated that oral galactose might prevent development of memory impairment in a rat model of sAD generated by intracerebroventricular administration of streptozotocin (STZ-icv). Here, we explored whether chronic oral galactose treatment could have beneficial effects on cognitive deficits already manifested at the time of initiation of galactose treatment in adult STZ-icv rats (treatment initiated 1 month after STZ-icv injection). The results clearly show that a 2-month exposure to oral galactose (200â¯mg/kg/day administered in a drink ad libitum) normalises impaired learning and memory functions. Memory improvement was accompanied by an improvement in brain glucose hypometabolism measured by 18fluorodeoxyglucose-positron emission tomography neuroimaging and by increments in active GLP-1 plasma levels as well as by an increased expression of GLP-1 receptors in the hippocampus and hypothalamus. Our findings provide strong evidence of beneficial effects of oral galactose treatment in the STZ-icv rat model of sAD and present possible underlying mechanisms including both direct effects of galactose within the brain and indirect GLP-1-induced neuroprotective effects that might open a new, dietary-based strategy in sAD treatment.
ناشر
Database: Elsevier - ScienceDirect (ساینس دایرکت)
Journal: Neuropharmacology - Volume 135, June 2018, Pages 48-62
Journal: Neuropharmacology - Volume 135, June 2018, Pages 48-62
نویسندگان
Ana Knezovic, Jelena Osmanovic Barilar, Ana Babic, Robert Bagaric, Vladimir Farkas, Peter Riederer, Melita Salkovic-Petrisic,